From: Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
Response
Treatment groups
Irinotecan plus S-1 [cases (%)]
S-1 monotherapy [cases (%)]
Total
61
62
CR
1 (1.6)
0 (0.0)
PR
14 (22.9)
6 (9.7)
SD
20 (32.8)
16 (25.8)
PD
14 (23.0)
26 (41.9)
Not assessable
12 (19.7)
14 (22.6)